NASDAQ:MEIP - MEI Pharma Stock Price, Forecast & News

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

MEI Pharma Inc (NASDAQ:MEIP) issued its earnings results on Thursday, November, 7th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.01. The firm earned $1.16 million during the quarter, compared to analyst estimates of $1.11 million. MEI Pharma had a negative return on equity of 79.27% and a negative net margin of 514.11%. View MEI Pharma's Earnings History.

MEI Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for MEI Pharma.

3 equities research analysts have issued twelve-month price objectives for MEI Pharma's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate MEI Pharma's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 296.8% from the stock's current price. View Analyst Price Targets for MEI Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.

Media headlines about MEIP stock have trended extremely negative recently, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MEI Pharma earned a daily sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for MEI Pharma.

MEI Pharma saw a increase in short interest in December. As of December 31st, there was short interest totalling 367,900 shares, an increase of 25.2% from the December 15th total of 293,800 shares. Based on an average daily volume of 418,900 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.6% of the shares of the stock are sold short. View MEI Pharma's Current Options Chain.

Some companies that are related to MEI Pharma include Revance Therapeutics (RVNC), RAPT Therapeutics (RAPT), XBiotech (XBIT), Akebia Therapeutics (AKBA), G1 Therapeutics (GTHX), Gossamer Bio (GOSS), Amphastar Pharmaceuticals (AMPH), Odonate Therapeutics (ODT), Radius Health (RDUS), Achillion Pharmaceuticals (ACHN), Phathom Pharmaceuticals (PHAT), Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals (KNSA), ZIOPHARM Oncology (ZIOP) and Applied Therapeutics (APLT).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include SCYNEXIS (SCYX), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Aurinia Pharmaceuticals (AUPH), Synergy Pharmaceuticals (SGYP), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), Novavax (NVAX), TG Therapeutics (TGTX) and Agile Therapeutics (AGRX).

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEIP stock can currently be purchased for approximately $2.52.

MEI Pharma has a market capitalization of $256.49 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.

The official website for MEI Pharma is http://www.meipharma.com/.

MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]